Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2410

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 5
Chunk 2410
---
 Common Stock
had not been in compliance with the Bid Price Requirement. On October 23, 2024, the trading price for CERo common stock closed under $0.10
and was the tenth consecutive trading day to do so. On October 24, 2024, the Company received a letter from the staff at The Nasdaq Global
Market notifying the Company that, because its Common Stock had a closing bid price of $0.10 or less for ten consecutive trading days,
it was no longer eligible to rely upon the 180-day cure period set forth in the Bid Price Requirement Letter.

On July 19, 2024, the Company
also received the MVPHS Letter notifying the Company that, for the 30 consecutive trading days prior to the date of the MVPHS Letter,
the Common Stock had not been in compliance with the MVPHS Requirement.

Such letters are in addition
to the letter from The Nasdaq Global Market received by the Company on May 2, 2024 (the “MVLS Letter” and, together with the
Bid Price Requirement Letter and the MVPHS Letter, the “Letters”) notifying the Company that, for the 30 consecutive trading
days prior to the date of such MVLS Letter, the Common Stock had traded at a value below the minimum $50,000,000 “Market Value of
Listed Securities” (“MVLS”) requirement set forth in Nasdaq Listing Rule 5450(b)(2)(A), which is required for continued
listing of the Common Stock on The Nasdaq Global Market (the “MVLS Requirement”). On October 30, 2024, the Company received
a letter from the staff at The Nasdaq Global Market notifying the Company that it had not regained compliance with the MVLS Requirement
within the 180-day compliance period set forth in the MVLS Letter.

Each of the Bid Price Requirement
and MVLS Requirement deficiencies results in the commencement of delisting proceedings. However, the Company attended a hearing before
the Nasdaq Panel on December 17, 2024, at which the Company submitted a plan for regaining compliance. Notwithstanding that applicable
Nasdaq rules provide a 180-day compliance period to regain compliance with the MVPHS Requirement, the plan submitted by the Company in
connection with such hearing, as required by applicable Nasdaq requirements, demonstrated a pathway to compliance with all applicable
deficiencies.

102

On January 17, 2025, the
N